• 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2021-03
  • 2020-08
  • 2020-07
  • 2020-03
  • 2019-11
  • 2019-10
  • 2019-09
  • 2019-08
  • 2019-07
  • br completing this research iPrevent has been pilot tested and


    completing this research, iPrevent has been pilot tested, and there was no evidence of an adverse impact on anxiety [32] and it H2DCFDA is now freely available for women to use online ( iprevent).
    Ethics approval was obtained from The University of Melbourne.
    Conflicts of interest
    There are no conflicts of interest to declare.
    This research was funded by the Australian National Health and Medical Research Council (NHMRC) (#1064244). KAP is an Australian National Breast Cancer Foundation Practitioner Fellow. JLH is a NHMRC Senior Principal Research Fellow.
    Appendix A. Supplementary data
    [1] Tian Q, Price ND, Hood L. Systems cancer medicine: towards realization of predictive, preventive, personalized and participatory (P4) medicine. J Intern Med 2012;271(2):111e21.
    [2] Valle I, Tramalloni D, Bragazzi NL. Cancer prevention: state of the art and future prospects. J Prev Med Hyg 2015;56(1):E21e7. [3] Chowdhury S, Dent T, Pashayan N, Hall A, Lyratzopoulos G, Hallowell N, Hall P, Pharoah P, Burton H. Incorporating genomics into breast and prostate cancer
    [4] Pashayan N, Hall A, Chowdhury S, Dent T, Pharoah PD, Burton H. Public health
    genomics and personalized prevention: lessons from the COGS project.
    [5] Couch FJ, Nathanson KL, Offit K. Two decades after BRCA: setting paradigms in personalized cancer care and prevention. Science 2014;343(6178):1466e70. [6] Hartmann LC, Lindor NM. The role of risk-reducing surgery in hereditary breast and ovarian cancer. N Engl J Med 2016;374(5):454e68. [7] Cancer Australia. Advice about familial aspects of breast cancer and epithelial ovarian cancer. Strawberry Hills, NSW: Cancer Australia; 2015. https://
    [8] Cuzick J, Sestak I, Bonanni B, Costantino JP, Cummings S, DeCensi A, Dowsett M, Forbes JF, Ford L, LaCroix AZ, Mershon J, Mitlak BH, Powles T, Veronesi U, Vogel V, Wickerham DL, S.C.o.B.C.O. Group. Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data. Lancet 2013;381(9880):1827e34.
    [9] Cuzick J, Sestak I, Forbes JF, Dowsett M, Knox J, Cawthorn S, Saunders C, Roche N, Mansel RE, von Minckwitz G, Bonanni B, Palva T, Howell A, investigators I-I. Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, rando-mised placebo-controlled trial. Lancet 2014;383(9922):1041e8.
    [10] Goss PE, Ingle JN, Ales-Martinez JE, Cheung AM, Chlebowski RT, Wactawski-Wende J, McTiernan A, Robbins J, Johnson KC, Martin LW, Winquist E, Sarto GE, Garber JE, Fabian CJ, Pujol P, Maunsell E, Farmer P, Gelmon KA, Tu D, Richardson H, Investigators NCMS. Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med 2011;364(25):2381e91.
    [11] Esserman LJ, Study W, Athena I. The WISDOM Study: breaking the deadlock in the breast cancer screening debate. NPJ Breast Cancer 2017;3:34. [12] Evans DG, Donnelly LS, Harkness EF, Astley SM, Stavrinos P, Dawe S, Watterson D, Fox L, Sergeant JC, Ingham S, Harvie MN, Wilson M, Beetles U, Buchan I, Brentnall AR, French DP, Cuzick J, Howell A. Breast cancer risk feedback to women in the UK NHS breast screening population. Br J Cancer 2016;114(9):1045e52.
    [13] Collins IM, Steel E, Mann GB, Emery JD, Bickerstaffe A, Trainer A, Butow P, Pirotta M, Antoniou AC, Cuzick J, Hopper J, Phillips KA, Keogh LA. Assessing and managing breast cancer risk: clinicians' current practice and future needs. Breast 2014;23(5):644e50.